Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|CALGB-49907||CALGB||A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens; Cyclophosphamide; Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC); Versus Capecitabine in Women 65 Years and Older with Node Positive or Node Negative Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|ANBL0531||COG||Response- and Biology-Based Therapy for Intermediate-risk Neuroblastoma: A Groupwide Phase III Study||Pediatric CIRB||Completed|
|ASCT1221||COG||A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myelomonocytic Leukemia (JMML)||Pediatric CIRB||Completed|
|NSABP-B-39||NSABP||A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0; I; or II Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|E3999||ECOG||A Randomized; Placebo-controlled; Double Blind; Trial of the Administration of the MDR Modulator; Zosuquidar Trihydrochloride (LY335979); During Conventional Induction and Post-Remission Therapy in Patients Greater than 60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia; Refractory Anemia with Excess Blasts in Transformation or High-Risk Refractory Anemia with Excess Blasts||Adult CIRB - Late Phase Emphasis||Completed|
|RTOG-0214||RTOG||A Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-30801||CALGB||A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|ADVL1221||COG||A Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination with Temsirolimus (IND# 61010) in Pediatric Patients with Recurrent or Refractory Solid Tumors||Pediatric CIRB||Completed|
|9855||ETCTN||A Phase 2 Study of CDX-011 (glembatumumab vedotin) for Metastatic Uveal Melanoma||Adult CIRB - Early Phase Emphasis||Completed|
|MDA2016-08-02||CP-CTNet_CLO-MD Anderson||A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer||Cancer Prevention and Control CIRB||Completed|